Protagenic Therapeutics
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.69
- Today's High:
- $1.8999
- Open Price:
- $1.7501
- 52W Low:
- $1.2488
- 52W High:
- $2.8
- Prev. Close:
- $1.799
- Volume:
- 9982
Company Statistics
- Market Cap.:
- $7.79 million
- Book Value:
- 1.25
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -27.17%
- Return on Equity TTM:
- -50.53%
Company Profile
Protagenic Therapeutics had its IPO on 2016-01-05 under the ticker symbol PTIX.
The company operates in the Healthcare sector and Biotechnology industry. Protagenic Therapeutics has a staff strength of 0 employees.
Stock update
Shares of Protagenic Therapeutics opened at $1.75 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.69 - $1.9, and closed at $1.75.
This is a -2.75% slip from the previous day's closing price.
A total volume of 9,982 shares were traded at the close of the day’s session.
In the last one week, shares of Protagenic Therapeutics have slipped by -4.4%.
Protagenic Therapeutics's Key Ratios
Protagenic Therapeutics has a market cap of $7.79 million, indicating a price to book ratio of 0.9968 and a price to sales ratio of 0.
In the last 12-months Protagenic Therapeutics’s revenue was $0 with a gross profit of $0 and an EBITDA of $-3557758. The EBITDA ratio measures Protagenic Therapeutics's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Protagenic Therapeutics’s operating margin was 0% while its return on assets stood at -27.17% with a return of equity of -50.53%.
In Q2, Protagenic Therapeutics’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Protagenic Therapeutics’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.76 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Protagenic Therapeutics’s profitability.
Protagenic Therapeutics stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.1293. Its price to sales ratio in the trailing 12-months stood at 0.
Protagenic Therapeutics stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $6.92 million
- Total Liabilities
- $1.51 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Protagenic Therapeutics ended 2024 with $6.92 million in total assets and $0 in total liabilities. Its intangible assets were valued at $6.92 million while shareholder equity stood at $5.41 million.
Protagenic Therapeutics ended 2024 with $0 in deferred long-term liabilities, $1.51 million in other current liabilities, 434.00 in common stock, $-27705062.00 in retained earnings and $0 in goodwill. Its cash balance stood at $219435.00 and cash and short-term investments were $6.04 million. The company’s total short-term debt was $394,309 while long-term debt stood at $0.
Protagenic Therapeutics’s total current assets stands at $6.92 million while long-term investments were $0 and short-term investments were $5.82 million. Its net receivables were $0 compared to accounts payable of $158172.00 and inventory worth $0.
In 2024, Protagenic Therapeutics's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Protagenic Therapeutics paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.75
- 52-Week High
- $2.8
- 52-Week Low
- $1.2488
- Analyst Target Price
- $4
Protagenic Therapeutics stock is currently trading at $1.75 per share. It touched a 52-week high of $2.8 and a 52-week low of $2.8. Analysts tracking the stock have a 12-month average target price of $4.
Its 50-day moving average was $1.96 and 200-day moving average was $1.92 The short ratio stood at 0.29 indicating a short percent outstanding of 0%.
Around 5153.1% of the company’s stock are held by insiders while 774.5% are held by institutions.
Frequently Asked Questions About Protagenic Therapeutics
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company’s lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.